Skip to main content
SpringerLink
Log in

Semaglutide: no increased risk of cardiovascular events

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine : 11 Jun 2019. Available from: URL: http://doi.org/10.1056/NEJMoa1901118

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Semaglutide: no increased risk of cardiovascular events. Reactions Weekly 1758, 10 (2019). https://doi.org/10.1007/s40278-019-63556-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-63556-5

Search

Navigation